Winkler K, Gaedicke G, Grosch-Wörner I, Marsmann G, Delling G, Landbeck G
Dtsch Med Wochenschr. 1977 Dec 16;102(50):1831-5. doi: 10.1055/s-0028-1105579.
The cyclic chemotherapy scheme OS I/75 was tried in 6 patients with newly diagnosed osteosarcoma and in 3 patients with secondary metastases. The treatment consists of high dose methotrexate, followed by citrovorum-factor rescue, doxorubicine (Adriblastin) and cyclophosphamide (Endoxan). All 6 primary patients are in a continuous remission of 6+ to 21+ months (median 12+ months). The length of remission in the patients with metastases is 5.5+ and 8+ months. The haematological side effects led to an average prolongation of the cycle by 11 days in a planned cycle duration of 42 days. However, they were readily manageable. Among the other side effects two cases of Adriblastin myocardiopathy are remarkable which became apparent after methotrexate and ifosfamide. In order to improve possibilities for treatment regional centralisation of patient care and interdisciplinary and supraregional cooperation of treatment centres are necessary. A prospective treatment programme has been developed for the Federal Republic of Germany and Austria.
对6例新诊断的骨肉瘤患者和3例继发转移患者试用了循环化疗方案OS I/75。治疗包括大剂量甲氨蝶呤，随后用甲酰四氢叶酸解救、多柔比星（阿霉素）和环磷酰胺（癌得星）。所有6例原发性患者均持续缓解6个月以上至21个月以上（中位缓解期12个月以上）。转移患者的缓解期为5.5个月以上和8个月以上。血液学副作用使计划周期时长42天的周期平均延长了11天。不过，这些副作用很容易控制。在其他副作用中，两例阿霉素心肌病较为显著，这在甲氨蝶呤和异环磷酰胺治疗后显现出来。为了改善治疗可能性，患者护理的区域集中化以及治疗中心的跨学科和超区域合作是必要的。已为德意志联邦共和国和奥地利制定了一项前瞻性治疗方案。
